This activity is supported by educational grants from:

• AstraZeneca
• AVEO Pharmaceuticals, Inc. (“AVEO Oncology”)
• Eisai
• Exact Sciences
• Fresenius Kabi USA, LLC
• Genentech, a member of the Roche Group
• GRAIL, LLC
• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
• Lilly
• Novartis
• Novocure
• Olympus Corporation of the Americas
  

This activity has been supported by an independent educational grant from:

• Gilead Sciences, Inc.

This activity is supported by a medical education grant from:

• Exelixis, Inc.
• Karyopharm Therapeutics

This project has been made possible in part by a grant from:

• Varian Medical Systems, a Siemens Healthineers company /Global Medical Education Grant Program

This activity has been supported by an unrestricted educational grant from:

• GE HealthCare, Pharmaceutical Diagnostics

This activity is supported by educational funding provided by:

• Amgen

View topics below or visit education.nccn.org/ac2022 for more information.

Plenary Sessions

• The Patient Journey: Access to Cancer Care
• The Patient Journey: Equity of Cancer Care
• The Patient Journey: Cancer Survivor Care

Best Practices in Oncology

• The Future of Telemedicine in Oncology
• State Legislation Addressing Specialty Pharmacy Policy
• Strategies and Initiatives to Improve New Patient Access to Cancer Care
  

Ampullary Adenocarcinoma

• Principles of Management of Patients with Ampullary Adenocarcinoma

Anal Cancer

• New Approaches for the Treatment of Patients with Anal Carcinoma

Bladder Cancer

• New Treatment Options for Patients with Bladder Cancer

Breast Cancer

• Locoregional Management of Patients with Early-Stage Breast Cancer
• NCCN Guidelines^® Updates: Management of Patients with HER2-Negative Breast Cancer
• Challenging Case Review: Breast Cancer

Colorectal Cancer

• Updates in Screening Recommendations for Colorectal Cancer
• Updates in the Treatment of Patients with Colorectal Cancer

Head and Neck Cancers

• Treatment De-Intensification for Patients with HPV-Positive Head and Neck Cancers

Hematologic Malignancies

• Optimizing Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Updates to the Management of Patients with Relapsed/Refractory Indolent B-Cell Lymphomas
• Updates to Management of Patients with Multiple Myeloma

Hepatocellular Carcinoma

• Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma

Medical Generics and Genomics

• Best Practices for Genetic Risk Assessment and Counseling

Non-Small Cell Lung Cancer

• Non-Small Cell Lung Cancer: Management of Patients with Resectable Disease
• Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer
• Challenging Case Review: Non-Small Cell Lung Cancer

Oncology Research

• Updates in Oncology: Oral Presentations from the NCCN Poster Sessions

Pancreatic Adenocarcinoma

• Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Prostate Cancer

• Management of Patients with Non-Metastatic Prostate Cancer

Skin Cancers

• Management of Patients with Aggressive Non-Melanoma Skin Cancers
• Management of Patients with Advanced Melanoma

Supportive Care and Survivorship

• Preventive Health in Cancer Survivors
• Cancer Screening and Surveillance Testing for Older Adult Cancer Survivors
• Vaccinations for Patients with Cancer and Cancer Survivors
• Pharmacogenetics in the Treatment and Supportive Care of Patients with Cancer